REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 202 filers reported holding REATA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 1.43 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,279,088 | +127808.8% | 12,545 | +46363.0% | 0.01% | – |
Q2 2022 | $1,000 | -87.5% | 27 | -88.4% | 0.00% | – |
Q1 2022 | $8,000 | +700.0% | 233 | +796.2% | 0.00% | – |
Q4 2021 | $1,000 | -92.3% | 26 | -80.0% | 0.00% | – |
Q3 2021 | $13,000 | -43.5% | 130 | -18.8% | 0.00% | – |
Q2 2021 | $23,000 | +666.7% | 160 | +384.8% | 0.00% | – |
Q1 2021 | $3,000 | – | 33 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 2,896,901 | $110,053,269 | 27.64% |
Ghost Tree Capital, LLC | 500,000 | $18,995,000 | 8.11% |
First Light Asset Management, LLC | 2,062,453 | $78,352,589 | 7.27% |
Boxer Capital, LLC | 1,230,004 | $46,727,852 | 2.46% |
Sofinnova Investments, Inc. | 992,029 | $37,687,182 | 2.24% |
Tri Locum Partners LP | 141,466 | $5,374,000 | 2.17% |
MPM BioImpact LLC | 194,181 | $7,376,936 | 1.91% |
Ikarian Capital, LLC | 201,200 | $7,643,588 | 1.84% |
KRS Capital Management, LLC | 28,141 | $1,069,077 | 1.46% |
EMERALD ADVISERS, LLC | 679,772 | $25,824,538 | 1.25% |